
Corcept Therapeutics Incorporated: updates and filings
Price
$67.79
November 18, 2026Market cap $7.2B
What Ploutos Investor adds for Corcept Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 15 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 3, 2026next Feb 1, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
July 2026
April 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 3, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 23, 2026Officer or director change, Regulation FD disclosureForm8-K
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 29, 2026Results of operations, Regulation FD disclosureForm8-K
- Jun 17, 2026Other material eventsForm8-K
- Jun 3, 2026Other material eventsForm8-K
- May 29, 2026Shares registered for employeesFormS-8
- May 28, 2026Officer or director change, shareholder voteForm8-K
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 21, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 17, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 25, 2026Other material eventsForm8-K
- Feb 24, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 24, 2026Results of operations, Regulation FD disclosureForm8-K
- Feb 19, 2026Other material eventsForm8-K
- Feb 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 22, 2026Other material eventsForm8-K
- Dec 31, 2025Other material eventsForm8-K
- Dec 11, 2025Letter from the SECFormUPLOAD
- Nov 4, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 3, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 23, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 29, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 29, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jun 17, 2026 | 8-K | Other material events | Document |
| Jun 3, 2026 | 8-K | Other material events | Document |
| May 29, 2026 | S-8 | Shares registered for employees | Document |
| May 28, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 21, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 17, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 25, 2026 | 8-K | Other material events | Document |
| Feb 24, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 24, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Feb 19, 2026 | 8-K | Other material events | Document |
| Feb 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 22, 2026 | 8-K | Other material events | Document |
| Dec 31, 2025 | 8-K | Other material events | Document |
| Dec 11, 2025 | UPLOAD | Letter from the SEC | Document |
| Nov 4, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 21, 2001.
The full analysis
What do Corcept Therapeutics's filings show?
The filings are where every one of Corcept Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.